Filtered By:
Cancer: Lymphoma

This page shows you your search results in order of relevance. This is page number 15.

Order by Relevance | Date

Total 355 results found since Jan 2013.

Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma
Abstract This Phase II trial evaluated the efficacy of bendamustine, bortezomib and rituximab in patients with previously untreated low‐grade lymphoma. Eligible patients had low grade lymphoma with no previous systemic disease treatment. Treatment for all patients was given in 28‐day cycles for a maximum of 6 cycles. Patients received rituximab 375 mg/m2 intravenously (IV) on days 1, 8 and 15 of cycle 1 and day 1 of cycles 2–6; bendamustine 90 mg/m2 IV on days 1 and 2; and bortezomib 1·6 mg/m2 IV on days 1, 8 and 15. Patients were permitted to begin maintenance treatment with rituximab 6 months after completion ...
Source: British Journal of Haematology - November 28, 2017 Category: Hematology Authors: Ian W. Flinn, Dana S. Thompson, Ralph V. Boccia, Gerald Miletello, Andrew Lipman, Douglas Flora, Daniel Cuevas, Steven W. Papish, Jesus G. Berdeja Tags: Research Paper Source Type: research

Excess Clinical Comorbidity Among HIV-Infected Patients Accessing Primary Care in US Community Health Centers.
CONCLUSIONS: As HIV-infected patients live longer, the increasing burden of noncommunicable diseases may complicate their clinical management, requiring primary care providers to be trained in chronic disease management for this population. PMID: 29262289 [PubMed - as supplied by publisher]
Source: Public Health Reports - December 22, 2017 Category: International Medicine & Public Health Tags: Public Health Rep Source Type: research

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial
Publication date: Available online 29 January 2018 Source:The Lancet Haematology Author(s): Mats Jerkeman, Christian Winther Eskelund, Martin Hutchings, Riikka Räty, Karin Fahl Wader, Anna Laurell, Helle Toldbod, Lone Bredo Pedersen, Carsten Utoft Niemann, Christina Dahl, Hanne Kuitunen, Christian H Geisler, Kirsten Grønbæk, Arne Kolstad Background Regimens based on ibrutinib alone and lenalidomide and rituximab in combination show high activity in patients with relapsed or refractory mantle cell lymphoma. We hypothesised that the combination of all three drugs would improve efficacy compared with previously published ...
Source: The Lancet Haematology - January 30, 2018 Category: Hematology Source Type: research

Cardiovascular disease incidence in adolescent and young adult cancer survivors: a retrospective cohort study
ConclusionWhile cancer therapies are known to increase the risk of CVD, this study additionally shows that CVD risk varies by sociodemographic factors.Implications for cancer survivorsThe identification and mitigation of CVD risk factors in these subgroups may improve long-term patient outcomes.
Source: Journal of Cancer Survivorship - February 9, 2018 Category: Cancer & Oncology Source Type: research

FDA works on new regulatory framework for AI
The U.S. Food and Drug Administration (FDA) is working on a new regulatory...Read more on AuntMinnie.comRelated Reading: FDA issues MR thermometry warning FDA proposes new path to 510(k) clearance FDA authorizes ACR to accredit DBT devices FDA releases update on breast implant lymphoma risk FDA clears Viz.ai's stroke detection software
Source: AuntMinnie.com Headlines - April 27, 2018 Category: Radiology Source Type: news

Sporadic Burkitt Lymphoma Mimicking an Adnexal Tumor
A 77-year-old woman, gravida 4, para 4, visited our department because of sudden onset left abdominal dull pain without any aggravating or relieving factor as well as left lower limb numbness, which had occurred for 2 weeks. No changing bowel habit and diarrhea were mentioned. She had diabetes mellitus and hypertension, and had a prior history of two episodes of stroke. She had not undergone prior pelvic surgery or Papanicolaou examination for cervical cancer screen. All previous births were by vaginal delivery.
Source: The Journal of Minimally Invasive Gynecology - June 13, 2018 Category: OBGYN Authors: Chung-Yuan Lee, Yeh Giin Ngo, Meng-Chih Lee, Yu-Che Ou, Chin-Jung Wang Source Type: research

Summary: International Kidney Cancer Symposium
Conclusions:  Ideal ischemia time is 20-25 minutes or less improves short and long term renal function. >25 minutes carried 5 year risk of new onset stage 4 CKD No differences on GFR for cold vs. warm ischemia times Preoperative GFR and the percent of kidney preserved was a better predictor of post op GFR.  No ischemia preserves renal function better than warm. Longer cold ischemia times were equivalent to shorter warm ischemia times. Quality and quantity of the remaining kidney is associated with ultimate renal function. Robotics in RCC Surgery Gennady Bratslavsky, MD The opening question ...
Source: Kidney Cancer Association - December 15, 2011 Category: Urology & Nephrology Source Type: news

miR-29b affects neurocyte apoptosis by targeting MCL-1 during cerebral ischemia/reperfusion injury.
Authors: Huang Z, Lu L, Jiang T, Zhang S, Shen Y, Zheng Z, Zhao A, Gao R, Li R, Zhou S, Liu J Abstract The present study aimed to determine whether an miRNA (miR)-29b inhibitor protected against cerebral ischemia/reperfusion (I/R) injury in vitro and to investigate the underlying mechanisms. As a model for induced cerebral IR injury, N2a cells were exposed to an oxygen-glucose deprivation/reoxygenation (OGD/R) environment. Using this model, it was demonstrated that miR-29b was significantly upregulated compared with cells in a normal environment. The interactions between miR-29b and myeloid cell leukemia sequence (...
Source: Experimental and Therapeutic Medicine - September 21, 2018 Category: General Medicine Tags: Exp Ther Med Source Type: research

Intravascular large B-cell lymphoma presenting as multiple stroke: A case report
Conclusion: IVLBCL is an aggressive disease with high mortality. Timely diagnosis and treatment can be lifesaving.
Source: Medicine - October 1, 2018 Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research

Medical Conditions Among Survivors of Adolescent and Young Adult Non-Hodgkin Lymphoma (NHL), Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)
Conclusion: This study found that sociodemographic factors were associated with the risk of developing medical conditions in AYA NHL, ALL and AML survivors. As expected, the risk of medical conditions varied by cancer type and treatment, with those undergoing SCT having a higher risk of medical conditions regardless of cancer type. NHL and ALL survivors who were uninsured or publicly insured were at a consistently higher risk of developing medical conditions, as were Hispanic ALL survivors and Black AML survivors. Our findings highlight the higher burden of medical conditions in subgroups of cancer survivors that may relat...
Source: Blood - November 21, 2018 Category: Hematology Authors: Keegan, T. H. M., Muffly, L. S., Li, Q., Alvarez, E., Brunson, A. M., Malogolowkin, M., Wun, T. Tags: 904. Outcomes Research-Malignant Conditions: Real World Outcomes Source Type: research

Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Richter's Syndrome:the SFGM-TC Experience
Conclusion. Our study suggests that allo-HCT is a strategy achieving prolonged survival but should be performed in young patients to limit the risk of NRM. The favorable impact of GVHd suggests an anti-RS allogenic effect.DisclosuresGuieze: abbvie: Honoraria; janssen: Honoraria; gilead: Honoraria.
Source: Blood - November 21, 2018 Category: Hematology Authors: Bounaix, L., Nguyen, S., Blaise, D., Michonneau, D., Bourhis, J.-H., Maertens, J., Poire, X., Chevallier, P., Maillard, N., Yakoub-Agha, I., Mannone, L., Bernard, M., de Revel, T., Labussiere-Wallet, H., Ceballos, P., Lemal, R., Hermet, E., Ravinet, A., T Tags: 732. Clinical Allogeneic Transplantation: Results: Poster II Source Type: research

Fool Me Once: An Uncommon Presentation of PE
​BY FREDDIE IRIZARRY-DELGADO; VAROON KAKAIYA; & AHMED RAZIUDDIN, MDAn 86-year-old African-American woman was brought to the ED by her daughter after two days of nutritional neglect, abdominal pain, and altered mental status. Her daughter said her mother felt lightheaded, appeared dehydrated, and vomited nonbilious watery fluid once. The patient had a history of diabetes mellitus type 2, DVT/PE, dementia, and early signs of parkinsonism.Her vital signs were remarkable only for tachypnea (24 bpm). Her troponin I was markedly elevated at 1.7 ng/mL. A D-dimer was ordered because of her history of unprovoked DVT/PE, and i...
Source: The Case Files - November 27, 2018 Category: Emergency Medicine Tags: Blog Posts Source Type: research

The Associations of Fruit and Vegetable Intakes with Burden of Diseases: A Systematic Review of Meta-Analyses
ConclusionsThis systematic review supports existing recommendations for fruit and vegetable intakes. Current comparative risk assessments might significantly underestimate the protective associations of fruit and vegetable intakes.
Source: Journal of the Academy of Nutrition and Dietetics - January 12, 2019 Category: Nutrition Source Type: research

DCA can improve the ACI-induced neurological impairment through negative regulation of Nrf2 signaling pathway.
CONCLUSIONS: TUDCA can alleviate the ACI-induced neurological impairment in rats through mitigating lipid peroxidation and inflammatory response and reducing apoptosis, whose relevant mechanism may be that TUDCA negatively regulates Nrf2 signaling pathway. PMID: 30657576 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - January 20, 2019 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Arterial thromboembolic events preceding the diagnosis of cancer in older persons
In conclusion, the risk of arterial thromboembolic events begins to increase 150 days before the date of cancer diagnosis in older persons and peaks in the 30 days before.
Source: Blood - February 21, 2019 Category: Hematology Authors: Navi, B. B., Reiner, A. S., Kamel, H., Iadecola, C., Okin, P. M., Tagawa, S. T., Panageas, K. S., DeAngelis, L. M. Tags: Plenary Papers, Free Research Articles, Thrombosis and Hemostasis, Clinical Trials and Observations Source Type: research